CombiGene AB (publ) (STO:COMBI)
Sweden
· Delayed Price · Currency is SEK 2.410
0.00 (0.00%)
Jun 23, 2025, 4:46 PM CET
CombiGene AB Company Description
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden.
The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment.
It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures.
The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions.
CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden.
CombiGene AB (publ)
| Country | Sweden |
| Founded | 1990 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Peter Ekolind |
Contact Details
Address: Agavagen 52A Lidingö, 181 55 Sweden | |
| Phone | 46 8 35 73 55 |
| Website | combigene.com |
Stock Details
| Ticker Symbol | COMBI |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0016101935 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peter Ekolind | Chief Executive Officer |
| Annika Ericson | Chief Scientific Officer |